Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

Status Recruiting

Clinical Trial Summary

Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first time since the incorporation of atropine penalization into amblyopia management, physicians can now offer Luminopia, an FDA-approved dual action dichoptic treatment, to patients with amblyopia. Since the product became commercially available in November 2022, the number of patients on Luminopia therapy continues to grow. This presents a unique opportunity to gather real world evidence from a large number of patients, representative of how ophthalmologists and optometrists are applying this novel treatment in the real world. A registry of the clinical data associated with Luminopia treatment, with IRB oversight, will provide answers to key scientific questions using a large dataset.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Amblyopia

Clinical Trial Details

NCT number	NCT06429280
Study type	Observational
Source	Luminopia
Contact
Status	Recruiting
Phase
Start date	September 1, 2023
Completion date	December 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04238065` - A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia	N/A
Completed	`NCT04432181` - Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
Terminated	`NCT02767856` - Regimens of Intermittent Occlusion Therapy for Amblyopia in Children	N/A
Completed	`NCT02458846` - Efficacy of Visual Screening in Ontario	N/A
Completed	`NCT01190813` - Levodopa for the Treatment of Residual Amblyopia	Phase 3
Completed	`NCT01109459` - Multimodal Physician Intervention to Detect Amblyopia	N/A
Completed	`NCT04313257` - Monocular Action Video Game Treatment of Amblyopia	N/A
Completed	`NCT04315649` - Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops	N/A
Completed	`NCT05223153` - OCT-A and Amblyopia
Recruiting	`NCT05522972` - Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games	N/A
Completed	`NCT01430247` - Vision Screening for the Detection of Amblyopia	N/A
Completed	`NCT02200211` - Study of Binocular Computer Activities for Treatment of Amblyopia	N/A
Withdrawn	`NCT04959422` - Assuring Ophthalmologic Follow up	N/A
Active, not recruiting	`NCT05612568` - 5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
Recruiting	`NCT03655912` - Binocular Visual Therapy and Video Games for Amblyopia Treatment.	N/A
Recruiting	`NCT06150391` - Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program	N/A
Completed	`NCT03754153` - Binocularly Balanced Viewing Study	N/A
Terminated	`NCT02246556` - Dichoptic Virtual Reality Therapy for Amblyopia in Adults	Phase 1
Withdrawn	`NCT02594358` - Caffeine in Amblyopia Study	Phase 1/Phase 2
Completed	`NCT02003235` - Assessment of Device for Treatment of Amblyopia	N/A